CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 269 enrolled
Drug / intervention
Dacarbazine +2 moredrug
Likely dose
Dacarbazine 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01359956
NCT01359956Phase 3Completed
CompareCT.gov

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study

National Cancer Institute, Naples·interventional·Posted May 25, 2011·Updated Apr 11, 2023

In Brief

A Phase 3 clinical trial evaluating Dacarbazine, Fotemustine, and 1 other intervention for Malignant Melanoma and Recurrent Melanoma. Completed, enrolled 269 participants.

Detailed Summary

This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma, Recurrent Melanoma
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 25, 2011
Enrollment StartApr 1, 2002
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 15.1 years ago

Interventions

Dacarbazinedrug

900 mg / m2 every 3 weeks

Fotemustinedrug

100 mg / m2 every 3 weeks

Interferon Alfa-2bdrug

5 M units every 3 weeks